Gilead Sciences
GILD
1,737 hedge funds and large institutions have $86.1B invested in Gilead Sciences in 2023 Q1 according to their latest regulatory filings, with 127 funds opening new positions, 671 increasing their positions, 713 reducing their positions, and 113 closing their positions.
23% more call options, than puts
Call options by funds: $1.01B | Put options by funds: $823M
12% more first-time investments, than exits
New positions opened: 127 | Existing positions closed: 113
2.01% more ownership
Funds ownership: 81.44% → 83.45% (+2%)
2% less capital invested
Capital invested by funds: $87.7B → $86.1B (-$1.58B)
6% less repeat investments, than reductions
Existing positions increased: 671 | Existing positions reduced: 713
2% less funds holding
Funds holding: 1,768 → 1,737 (-31)
30% less funds holding in top 10
Funds holding in top 10: 64 → 45 (-19)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$630M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$370M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$324M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$304M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$256M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$414M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$302M |
| 3 |
Millennium Management
New York
|
-$229M |
| 4 |
Man Group
London,
United Kingdom
|
-$190M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$145M |
GILD Hedge Fund Activity: Q1 2023 in Review
1,737 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2023, worth a combined $86.1B — down 1.8% from $87.7B a quarter earlier.
Buyers outnumbered sellers: 127 funds opened new GILD positions and 113 closed out — a net gain of 14 holders — while 671 added to existing stakes and 713 trimmed.
The largest buyer was Capital World Investors, adding an estimated $630M. The largest seller was BlackRock, cutting an estimated $414M.
- 1,737 institutional investors held Gilead Sciences (GILD) as of Q1 2023, down from 1,768 in Q4 2022.
- Funds reported $86.1B of Gilead Sciences stock for Q1 2023, down 1.8% quarter-over-quarter.
- 127 funds opened new Gilead Sciences positions in Q1 2023 and 113 closed out, a net change of +14 holders.
- The largest Gilead Sciences buyer in Q1 2023 was Capital World Investors, an estimated $630M added.
- The largest Gilead Sciences seller in Q1 2023 was BlackRock, an estimated $414M sold.
Based on aggregated 13F filings for Q1 2023.